Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Allbirds Inc (BIRD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Allbirds Inc — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $223.48 (market cap $29.60B), while Allbirds Inc trades at $2.59 (market cap $30.00M). The key difference: Alnylam Pharmaceuticals, Inc. is far larger — about 986.7× Allbirds Inc's market cap. Which is the better fit depends on your goals.
| ALNY | BIRD | |
|---|---|---|
Market Cap | $29.60B | $30.00M |
Sector | Health | Consumer Cyclical |
52-Week High | $491.22 | $16.99 |
52-Week Low | $205.48 | $2.21 |
Enterprise Value | $27.56B | $48.86M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $222.54, up 2.56% today, amid a bearish technical signal with support at $218 and resistance at $223. The company reported strong revenue growth to $3.71B in 2025 and turned profitable with net income of $313.75M, though recent Q2 2026 earnings missed estimates. Analyst consensus remains bullish with a $370.07 price target, but multiple law firms are investigating potential securities fraud, creating near-term uncertainty.
The outlook is mixed: robust fundamentals and analyst support suggest long-term upside, but legal risks and recent earnings volatility pose significant headwinds. Investors face tension between strong profitability metrics and heightened sentiment risks from ongoing investigations.
BIRD stock trades at $2.61, up 1.16% with a bullish technical signal despite mixed moving averages. The company has pivoted from footwear to AI infrastructure, rebranding as Smartbird in June 2026. Revenue declined from $298M in 2022 to $152M in 2025, with persistent negative net margins (-53.36%) and cash burn. Analyst consensus shows 21% buy ratings amid high hold percentage.
The outlook hinges on successful AI strategy execution, but significant risks include sustained losses, declining revenue, and cash flow challenges. Current valuation at P/S 0.15 appears low, yet profitability remains distant. Investors face binary outcome: AI pivot success could drive upside, while failure risks further declines.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Allbirds Inc
Allbirds Inc is a global lifestyle brand that innovates with naturally derived materials to make footwear and apparel products. Its primary source of revenue is from sales of shoes and apparel products in its directly owned digital and physical retail channels.
Read more on BIRD →
